Sirius Therapeutics News and Activities

Acquisition, funding and merger involving Sirius Therapeutics.

• Sirius Therapeutics has just announced a $50 Million fundraising (posted on June 16 2025).

View the org chart displaying its 12 main executives

Most searched biographies at Sirius Therapeutics

• Qunsheng Ji, Chief Executive Officer and Director
• David Wang, Chairman of the Board
• Douglas Fambrough, Independent Director

Create your alert
to follow the executive moves at Sirius Therapeutics.

Sirius Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Sirius Therapeutics

• SRSD216 Demonstrates Sustained Lp(a) Reduction and Favorable Safety Profile in Phase 1 Trial-Sirius Therapeutics, Inc.
• Sirius Therapeutics Announces First Patient Dosed in Phase 2 Trial of SRSD107 for Chronic Coronary and/or Peripheral Arterial Disease-Sirius Therapeutics, Inc.
• Sirius Therapeutics Announces First Patient Dosed in Phase 2 Trial of SRSD216 for siRNA Therapy for Hyperlipoproteinemia(a)-Sirius Therapeutics, Inc.
• Sirius Therapeutics and CRISPR Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe-Sirius Therapeutics, Inc.
• Sirius Therapeutics, Inc.
• Sirius Therapeutics, Inc.
• Sirius Therapeutics Receives European Medicines Agency (EMA) Authorization to Initiate a Phase 2 Clinical Trial of SRSD107 for Thromboembolic Disorders-Sirius Therapeutics, Inc.
• Sirius Therapeutics and CRISPR Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies-Sirius Therapeutics, Inc.
• Sirius Therapeutics Announces Nearly $50 million Financing to Accelerate Clinical Development of siRNA Therapeutics for Cardiometabolic Diseases-Sirius Therapeutics, Inc.
• Sirius Therapeutics announces U.S. FDA Clearance of IND to Begin Clinical Trial of Novel siRNA Therapy for Hyperlipoproteinemia(a)-Sirius Therapeutics, Inc.
• View more press releases Close

Social media about Sirius Therapeutics

• Sirius Therapeutics on Wikipedia, Google News & Yahoo Finance
• Sirius Therapeutics on LinkedIn, X (Twitter) & YouTube